Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting / Carlos Esteban Builes Montaño    

Público ISBD Título : Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Fecha de publicación : 2022 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : type 2 diabetes  insulin degludec  liraglutide  IDegLira  real-world evidence (RWE) Resumen : Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting. Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events. Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline. Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts. Mención de responsabilidad : Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco, José F. Botero-Arango Referencia : Front Endocrinol (Lausanne). 2022 Apr 28;13:828607. DOI (Digital Object Identifier) : 10.3389/fendo.2022.828607 PMID : 35573995 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fendo.2022.828607/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6027 Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting [documento electrónico] / Carlos Esteban Builes Montaño,  . - 2022. Obra : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : type 2 diabetes  insulin degludec  liraglutide  IDegLira  real-world evidence (RWE) Resumen : Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting. Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events. Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline. Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts. Mención de responsabilidad : Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco, José F. Botero-Arango Referencia : Front Endocrinol (Lausanne). 2022 Apr 28;13:828607. DOI (Digital Object Identifier) : 10.3389/fendo.2022.828607 PMID : 35573995 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fendo.2022.828607/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6027

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001868	AC-2022-033	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

AC-2022-033 Adobe Acrobat PDF

Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions / Luis Vicente Syro Moreno  

Público ISBD Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000777	AC-2018-064	Archivo digital	Producción Científica	Artículos científicos	Disponible

Progress in the Diagnosis and Classification of Pituitary Adenomas / Luis Vicente Syro Moreno  

Público ISBD Título : Progress in the Diagnosis and Classification of Pituitary Adenomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Diagnosis  genetics  pathology  acromegaly  multiple endocrine neoplasia type 1  pituitary adenoma  familial isolated  carney complex Resumen : Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Alex Ramirez, Antonio Di Ieva, Murat Aydin Sav, Lina M Restrepo, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2015 Jun 12;6:97. DOI (Digital Object Identifier) : 10.3389/fendo.2015.00097 PMID : 26124750 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2015.00097/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3893 Progress in the Diagnosis and Classification of Pituitary Adenomas [documento electrónico] / Luis Vicente Syro Moreno,  . - 2015. Obra : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Diagnosis  genetics  pathology  acromegaly  multiple endocrine neoplasia type 1  pituitary adenoma  familial isolated  carney complex Resumen : Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Alex Ramirez, Antonio Di Ieva, Murat Aydin Sav, Lina M Restrepo, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2015 Jun 12;6:97. DOI (Digital Object Identifier) : 10.3389/fendo.2015.00097 PMID : 26124750 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2015.00097/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3893

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000473	AC-2015-026	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 3 / 3) Por página: 25 50 100 200